PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-224315.95%
Negative net income growth while AGEN stands at 5.05%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
418.75%
Some D&A expansion while AGEN is negative at -65.66%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
2984.50%
SBC growth while AGEN is negative at -10.99%. John Neff would see competitor possibly controlling share issuance more tightly.
29070.41%
Well above AGEN's 83.33% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5571250.00%
AP growth well above AGEN's 196.36%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.
12125.42%
Growth well above AGEN's 76.63%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
753.88%
Well above AGEN's 218.92%. Michael Burry would worry about large intangible write-downs or revaluation gains overshadowing real performance.
-298628.16%
Negative yoy CFO while AGEN is 9.85%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
-260.15%
Negative yoy CapEx while AGEN is 93.36%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-260.15%
We reduce yoy invests while AGEN stands at 93.36%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.